How the WIN consortium achieves its goals

Latest data from KEYNOTE 42: Pembrolizumab vs chemotherapy in treatment-naive patients (pts) with PD-L1 advanced NSCLC

Entrectinib in NTRK fusion-positive non-small cell lung cancer

Using CT imaging to find radiomic signatures in surgically resected NSCLC

The role of afatinib in patients with EGFR NSCLC

Accelerated tumour growth due to immunotherapy: Fact or fiction?

Biomarkers of systemic inflammation linked to reduced clinical activity of atezolizumab monotherapy in metastatic TNBC

KEYNOTE-028 and KEYNOTE-158: Pembrolizumab as treatment for advanced SCLC after two or more lines of prior therapy

5' UTR mutations in prostate cancer

Cancer preventive vaccine used in mouse model of Lynch syndrome

ADMIRAL: Gilteritinib as treatment for patients with relapsed or refractory acute myeloid leukaemia

Immunomodulatory effects of PARP inhibition in BRCA1-deficient triple-negative breast cancer